OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer

V Baylot1,2, C Andrieu1,2, M Katsogiannou1,2, D Taieb1,2, S Garcia1,2, S Giusiano1,2, J Acunzo1,2, J Iovanna1,2, M Gleave3, C Garrido4 and P Rocchi1,2

Despite many advances in oncology, almost all patients with pancreatic cancer (PC) die of the disease. Molecularly targeted agents are offering hope for their potential role in helping translate the improved activity of combination chemotherapy into improved survival. Heat shock protein 27 (Hsp27) is a chaperone implicated in several pathological processes such as cancer. Further, Hsp27 expression becomes highly upregulated in cancer cells after chemotherapy. Recently, a modified antisense oligonucleotide that is complementary to Hsp27 (OGX-427) has been developed, which inhibits Hsp27 expression and enhances drug efficacy in cancer xenograft models. Phase II clinical trials using OGX-427 in different cancers like breast, ovarian, bladder, prostate and lung are in progress in the United States and Canada. In this study, we demonstrate using TMA of 181 patients that Hsp27 expression and phosphorylation levels increase in moderately differentiated tumors to become uniformly highly expressed in metastatic samples. Using MiaPaCa-2 cells grown both in vitro and xenografted in mice, we demonstrate that OGX-427 inhibits proliferation, induces apoptosis and also enhances gemcitabine chemosensitivity via a mechanism involving the eukaryotic translation initiation factor 4E. Collectively, these findings suggest that the combination of Hsp27 knockdown with OGX-427 and chemotherapeutic agents such as gemcitabine can be a novel strategy to inhibit the progression of pancreas cancer.

Cell Death and Disease (2011) 2, e221; doi:10.1038/cddis.2011.104; published online 20 October 2011

Subject Category: Cancer

Pancreatic cancer (PC) remains one of the most deadly and chemoresistant cancers. Multiple studies have evaluated various chemotherapeutic agents, but a few have produced significant improvement in survival.1 Gemcitabine remains the first-line drug for the treatment of advanced PC, either alone or in combination with other chemotherapeutic agents. However, the inherent resistance of PC to currently available chemotherapeutic agents presents a major challenge.1–3 Identification of robust new molecular target and relevant pathways to restore sensitivity to chemotherapeutic agents is a top priority.4 Several mechanisms like STAT3, NF-κappaB and interferon-gamma helps in cytotoxic effect of gemcitabine.19 Antisense oligonucleotides (ASOs) are powerful tools that specifically hybridize with complementary mRNA regions forming RNA/DNA duplexes to inhibit target gene expression in a sequence-specific manner. Several gene-targeting ASOs in combination with other compounds, such as chemotherapeutic agents, have shown synergistic anti-neoplastic effects in several tumor models. Recently, Hsp27 ASO and short interference RNA (siRNA) were reported to potently inhibit Hsp27 expression in human prostate PC-3 cells with increased caspase-3 cleavage, apoptosis and 87% suppression of cell growth.8,9 A second generation ASO-targeting Hsp27 (OGX-427) is currently tested in phase II clinical trials for prostate, bladder, ovarian, breast and lung cancers in the United States and Canada.21

In this study, we have been able to associate Hsp27 expression with bad prognosis in PC patients. Further, we

1INSERM, U866 'Stress Cellulaire', Parc Scientifique et Technologique de Luminy, Marseille, France; 2Aix-Marseille Université, Campus de Luminy, Marseille, France; 3The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada and 4INSERM, U866, Faculty of Medicine, Dijon, France

Corresponding author: P Rocchi, INSERM, U864 'Stress Cellulaire', Parc Scientifique et Technologique de Luminy, 163 avenue de Luminy, 13289 Marseille, France.

Tel: +33 491 828 808; Fax: +33 491 826 083; E-mail: palma.rocchi@inserm.fr

Keywords: Hsp27; oligonucleotide antisense; pancreas cancer xenograft; eIF4E; gemcitabine chemoresistance

Abbreviations: ASO, antisense oligonucleotide; Hsp27, heat shock Protein 27; eIF4E, eukaryotic translation initiation factor 4E; TMA, tissue microarrays; PC, pancreatic cancer; IPMNP, intraductal papillary mucinous neoplasms of the pancreas; EPT, endocrine pancreas; ADK, adenocarcinoma; WD, well-differentiated; MD, moderately-differentiated; UD, undifferentiated; Meta, metastatic; TCL, total cell lysate; IP, immunoprecipitation; IB, immunoblotting

Received 01.6.11; revised 06.9.11; accepted 16.9.11; Edited by P Salomoni
have explored the role of Hsp27 in PC cell survival using MiaPaCa-2 cells grown both in vitro and in vivo, and identified a function for Hsp27 in promoting cell growth and chemoresistance.

Results

Hsp27 immunostaining increases in undifferentiated and metastatic human PC. To study the role of Hsp27 in PC, we determine its expression level by immunostaining in 181 pancreas cancer specimens spotted on a tissue microarray (TMA). Hsp27 was found mostly in the cytoplasm of epithelial cells of tumor glands (Figure 1a). More specifically, while Hsp27 staining was absent or weak in less aggressive tumors like intraductal papillary mucinous neoplasms of the pancreas (IPMNP) and endocrine pancreas tumors (EPT), it strongly increased with the loss of differentiation in pancreas adenocarcinomas (ADK). Further, pancreatic tumors from metastatic sites exhibited uniform and highly positive Hsp27 staining in all specimens. The mean intensity scored in percentage of numerous and massive positive cells in IPMNP, EPT, well-differentiated (WD) ADK, moderately/undifferentiated (MD/UD) ADK and metastatic (Meta) samples were 42%, 43%, 68%, 71% and 90%, respectively (Figure 1b).

Overexpression of Hsp27 inhibits gemcitabine-induced apoptosis and promotes tumor growth while Hsp27 down-regulation has the opposite effects. In order to determine whether Hsp27 overexpression could be part of PC cell’s resistance to the first-line chemotherapeutic agent gemcitabine, we established a MiaPaCa-2 cell line stably expressing human Hsp27 cDNA (MiaPaCa-2-Hsp27). We first confirmed, by western blot, elevated Hsp27 protein levels in MiaPaCa-2-Hsp27 as compared with MiaPaCa-2 stably expressing the empty vector (MiaPaCa-2-Mock) (Figure 2a). After 24 h treatment with gemcitabine (see Materials and Methods) cell viability studies showed that MiaPaCa-2-Hsp27 cells were more resistant to gemcitabine-induced apoptosis compared with Mock cells (Figure 2b). Flow cytometry analysis revealed that Hsp27 overexpression increased the resistance to apoptosis induced by gemcitabine while decreasing the percentage of cells in sub G0 phase (Figure 2c). Conversely, OGX-427, an oligonucleotide antisense of second generation (WD) ADK, moderately/undifferentiated (MD/UD) ADK and metastatic (Meta) samples were 42%, 43%, 68%, 71% and 90%, respectively (Figure 1b).

Overexpression of Hsp27 inhibits gemcitabine-induced apoptosis and promotes tumor growth while Hsp27 down-regulation has the opposite effects. In order to determine whether Hsp27 overexpression could be part of PC cell’s resistance to the first-line chemotherapeutic agent gemcitabine, we established a MiaPaCa-2 cell line stably expressing human Hsp27 cDNA (MiaPaCa-2-Hsp27). We first confirmed, by western blot, elevated Hsp27 protein levels in MiaPaCa-2-Hsp27 as compared with MiaPaCa-2 stably expressing the empty vector (MiaPaCa-2-Mock) (Figure 2a). After 24 h treatment with gemcitabine (see Materials and Methods) cell viability studies showed that MiaPaCa-2-Hsp27 cells were more resistant to gemcitabine-induced apoptosis compared with Mock cells (Figure 2b). Flow cytometry analysis revealed that Hsp27 overexpression increased the resistance to apoptosis induced by gemcitabine while decreasing the percentage of cells in sub G0 phase (Figure 2c). Conversely, OGX-427, an oligonucleotide antisense of second generation specific for Hsp27 that induced a dose-dependent down-regulation of Hsp27 (Figures 2d and e), inhibited cell growth (Figure 2f), induced apoptosis (Figure 2g) and sensitized MiaPaCa-2 cells to gemcitabine (Figure 2h).

OGX-427 inhibits proliferation and sensitizes to gemcitabine via inhibition of the eukaryotic translational initiation factor 4E (eIF4E). We recently showed in prostate cancer cells that a relevant pathway through which Hsp27 inhibits apoptosis was by its interaction with eIF4E thereby protecting this translational factor from its degradation. We therefore studied here the effect of OGX-427 treatment in eIF4E stability. We found that in OGX-427-treated MiaPaCa-2 cells, there was a decrease of ~70% in eIF4E protein at 70 nM (Figures 3a and b). Consistent with this result, eIF4E content was increased in MiaPaCa-2-Hsp27 compared with MiaPaCa-2-Mock (Figure 3c). Hsp27 regulated eIF4E protein expression, without affecting its mRNA expression (data not shown) but by inducing a decrease of ~30% in the amount of ubiquitinated eIF4E (Figures 3d and e) thereby inhibiting its proteasomal degradation as we already reported. As Hsp27 has been shown to induce resistance to cell death in other cancer cell models by interacting with different cellular partners, we recently showed the relevance of eIF4E in Hsp27-induced resistance to gemcitabine in PC cells. We depleted eIF4E by means of a specific siRNA and studied the protective effect of Hsp27. We found that when eIF4E was depleted, Hsp27 was unable to modify the sensitivity of the cells to gemcitabine, suggesting the relevance of Hsp27-eIF4E association (Figure 3f).

Collectively, the results illustrated in Figure 3 and data previously published by us indicates that Hsp27 levels correlate with those of eIF4E. Further, Hsp27 interacts directly with eIF4E inhibiting its ubiquitination and proteasomal degradation.

Hsp27 association with eIF4E involves its C-terminal region and depends on the phosphorylation of the chaperone. In order to analyze Hsp27-eIF4E interaction, we used Hsp27 deletion mutants previously described by Al-Madhoun et al. The C-terminal mutant Hsp27 N1 (1–93) lacks part of the α-crystallin domain, believed to mediate oligomerization of Hsp27. The Hsp27 N2 mutant (1–173) lacks the flexible domain (IXI box) at the C-terminal, believed to be involved in the formation of multiple inter-subunit interactions. Finally, the N-terminal mutant, Hsp27 C1 (93–205), lacks the hydrophobic WDFP domain and the major phosphorylation sites necessary for interacting with other proteins and molecular chaperone function (Figure 4a).

Immunoprecipitation of eIF4E followed by immunoblot analysis with anti-histidine antibody was performed on MiaPaCa-2 cells transiently transfected with constructs carrying wild type (WT) and Hsp27 truncated mutant forms (N1, N2 and C1). As shown in Figure 4b, eIF4E was able to interact with WT-Hsp27 and N2, while hardly no or weak interaction was observed with N1 and C1, respectively. Interestingly, only transfection with N2 protected MiaPaCa-2 pancreatic cells to gemcitabine-induced apoptosis (protection similar to that observed with WT-Hsp27). In contrast, transfection with N1 or C1 sensitizes MiaPaCa-2 pancreatic cells to gemcitabine (Figure 4c). These results suggest that cytoprotection induced by Hsp27 in MiaPaCa-2 cells seems to involve eIF4E interaction.

Phosphorylation of the 3 Serine (Ser) residues of Hsp27 (position 15, 78 and 82) has been shown to modulate Hsp27 functions. To analyze the effect of Hsp27 phosphorylation on its association with eIF4E, we used two phospho-mutants (3D and 3A) of Hsp27 (Figure 5a). The 3D have the three Ser residues replaced by aspartates that mimics the constitutively phosphorylated protein. The 3A have the three Ser residues replaced by alanines that mimic the constitutively dephosphorylated protein. We found that the constitutively phosphorylated 3D mutant bound to eIF4E more efficiently than WT, while the non-phosphorylatable 3A mutant was unable to do so (Figure 5b). Thus, Hsp27 phosphorylation considerably increases eIF4E interaction.
Phosphorylated Hsp27: a bad prognosis marker in PC. Previous studies demonstrated that phosphorylation levels of Hsp27 increased in advanced tumors and correlate with treatment resistance.23,27 Similarly, our results shown above suggest that the phosphorylation of Hsp27 (P-Hsp27) was necessary to confer resistance to gemcitabine. This suggests that P-Hsp27 could be used as bad prognosis factor in PC. To explore this hypothesis, we checked Hsp27 phosphorylation status in human TMA. Figure 6 illustrates that total- and P-Hsp27 are low in WD ductal ADK, strongly increased with the loss of differentiation to become uniformly highly positive in PC from metastatic sites. The increased levels of P-Hsp27 correlated with total-Hsp27 and eIF4E. This result is consistent with recent work published by Taba et al.27 showing that Hsp27 is phosphorylated in gemcitabine-resistant PC. Our results suggest that gemcitabine resistance might involve eIF4E.
Anti-cancer effect of OGX-427 in vivo. Male nude mice bearing MiaPaCa-2 tumors were randomly selected for treatment with OGX-427 or an ASO control administered alone, or in combination with gemcitabine (see Materials and Methods). Mean tumor volume was similar in all groups before therapy (300–500 mm$^3$ size). Figures 7a and b show
that OGX-427 monotherapy significantly reduced MiaPaCa-2 tumor volume by up to ~50% from day 14 to 35 (*P ≤ 0.05; **P ≤ 0.01). Moreover, treatment with OGX-427, compared with ASO control, significantly enhanced the apoptotic effect of gemcitabine in vivo, reducing mean MiaPaCa-2 tumor volume by ~50%, 28 days after initiation of treatment (**P ≤ 0.01; Figures 7a and b). Under the experimental conditions described above, no adverse effects were observed. Microscopic studies in tumor slides confirmed that the anti-tumor effect of OGX-427 was associated with a
decrease in Hsp27, eIF4E and ki67 proliferation index and an increase in caspase-3-dependent apoptosis (Figure 7c).

**Discussion**

Hsp27 expression is induced by various stressors, such as chemotherapy and can act at multiple control points in apoptotic pathways to ensure that stress-induced damage does not inappropriately trigger cell death. Several mechanisms account for the cytoprotective effect of Hsp27, including: (1) chaperone inhibitor of protein misfolding; (2) inhibition of key effectors of the apoptotic machinery at the pre- and post-mitochondrial level; and (3) proteasome-mediated degradation of proteins under stress conditions. Targeting Hsp27 by the second generation ASO, OGX-427, inhibited Hsp27 expression and enhanced drug sensitivity in several xenograft models. Although mechanisms by which Hsp27 inhibits apoptosis are partially defined, its role in PC growth remains less clear.

In this study, we identified using TMA of 181 specimens that Hsp27 and P-Hsp27 are highly overexpressed in UD PC to become uniformly and highly expressed in metastatic tumors. The highly uniform expression of Hsp27 in metastatic lesions further underscores the association of Hsp27 with the lethal component of the disease. Recently, Mori-Iwamoto et al. demonstrated that Hsp27 is a biomarker of resistance of PC cells to gemcitabine and its downregulation mediated by interferon-gamma contributes to gemcitabine cytotoxic...
effect.\(^\text{19}\) We extend these observations in this work showing that increased Hsp27 levels confer antiapoptotic advantage enhancing gemcitabine apoptosis in chemoresistant MiaPaCa-2 model. Knockdown of Hsp27 in MiaPaCa-2 cells using siRNA silencing and induces apoptosis in vitro and in vivo. Furthermore, additive effect was observed when MiaPaCa-2 cells or xenografts were treated with OGX-427 plus gemcitabine.

The mammalian target of rapamycin (mTOR) pathway (eIF4E), has been described to regulate cell survival, and was recently recognized as therapeutic target in several cancers\(^\text{30}\) including PC.\(^\text{31}\) In most systems, cap-dependent translation depends on eIF4E levels and eIF4E can exert oncogenic effects when overexpressed.\(^\text{32,33}\) Previous studies have shown that the mTOR pathway is constitutively active in serum-starved MiaPaCa-2 cells\(^\text{14}\) and that eIF4E is upregulated in PC compared with normal cells.\(^\text{31}\) Recently, we found that Hsp27 affects eIF4E stability, mediating chemoresistance of advanced prostate cancer.\(^\text{22}\) In this report, we demonstrate in MiaPaCa-2 model that changes in Hsp27 expression serve as an upstream regulator of eIF4E. Moreover, we show that Hsp27 and P-Hsp27 levels are directly correlated with eIF4E.

In spite of the importance of eIF4E, little is known about its regulation and role in PC chemoresistance. Transcription of eIF4E gene is induced in response to many stimuli including serum and growth factors.\(^\text{35}\) However, mechanisms regulating eIF4E protein expression remain undefined. Othumpangat \textit{et al.}\(^\text{36}\) recently reported that eIF4E is ubiquitinated and degraded in a proteasome-dependent manner. Ubiquitin is a low-molecular-weight polypeptide covalently conjugated to lysine residues in target proteins that serve as signal for delivery to and proteolysis by the proteasome.\(^\text{37}\) The ubiquitin–proteasome pathway is an important factor controlling the expression and activity of regulatory proteins, such as transcription factors, cell cycle regulators and signal transduction proteins.\(^\text{38}\) We recently showed in prostate cancer model that the ubiquitin–proteasome pathway regulates the turnover of eIF4E and cell proliferation. We reported that eIF4E complexes with Hsp27 that induced androgen withdrawal and paclitaxel chemoresistance.\(^\text{39}\) Here we demonstrated Hsp27–eIF4E interaction contributes to the overall gemcitabine resistance in MiaPaCa-2 cells and this interaction is favored by phosphorylation of Hsp27.

In summary, the results of this study support the hypothesis that increased Hsp27 in UD and metastatic PC is an adaptive response enhancing cell survival. Hsp27 silencing using OGX-427 alters eIF4E signaling, enhances apoptosis, potentiates gemcitabine activity and offers a new treatment strategy to delay progression of PC. These results provide preclinical proof of principle for the use of OGX-427 as a novel therapeutic strategy in the treatment of PC.

Materials and Methods

Pancreas tissue specimens. Archival resection specimens from 181 patients were studied. Tissue fragments were processed in the Pathology Department, Hôpital Nord (SG). All samples used for TMA construction were fixed in buffered formalin and paraffin embedded. Differentiation and pathological staging were assessed by histological examination according to criteria defined by Kloppel \textit{et al.}\(^\text{39}\) Histopathological diagnoses were: IPMNP \((n = 13), \text{EPT} (n = 24), \text{ductal ADK} ((n = 65), \text{MD}; n = 12) \text{and} (UD; n = 21)\) and Meta of pancreatic ductal ADK (peritoneal n = 25, liver n = 21).

TMA analysis. TMA were prepared as previously described.\(^\text{40}\) For each tumor, two representative tumor areas were delineated by circling within tissue sections appropriate areas with a permanent black pen on hematoxylin- and eosin-stained paraffin sections to guide the punches of cores. Cores were sampled using the ALPHELYSEN Arraying Device (ALPHELYSEN, Plaisir, France). Core cylinders of 0.6 mm diameter, punched from the donor block, were then deposited in the recipient paraffin block. TMA sections (4 mm thick) were cut 24 h before immunohistochemical (IHC) processing.

Immunostaining. The IHC procedure was performed with a Ventana Benchmark autostainer (Ventana, Illkirch, France) using the manufacturer procedure and kit as previously reported.\(^\text{40}\) Slides were incubated for 32 min at 37°C with specific antibodies from Nova Castra (Newcastle, UK) for total Hsp27, stressgen for the phospho Hsp27 (P-Hsp27) and Cell Signaling technology, Inc. (Danvers, MA, USA) for eIF4E at the concentration of 1/100 in 1% BSA primary antibodies.

Scoring of Hsp27 staining. TMA analysis using the SAMBA 2050 automated device (TRIBVN/SAMBA Technologies, Chaillon, France) was performed according to the protocol previously described.\(^\text{40}\) SAMBA ‘immuno’ software was applied. Several parameters per core were computed: the area of counterstaining, the ratio (as percentage) of the positive area vs counterstained areas and a quick score (percentage of positive area mean optical density (OD)). OD was evaluated on a scale of grey levels (arbitrary units) ranging from 0 to 255. The computation of each parameter obtained provided numerical values consisting of continuous variables for statistical tests.
**Tumor cell line.** The human chemoresistant PC cell line MiaPaCa-2 obtained from the American Type Culture Collection was maintained in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal calf serum. Cells were routinely grown in 50 ml flasks at 37°C in a humidified 5% CO2–95% air atmosphere.

**Lentiviral Infection of MiaPaCa-2 cells with Hsp27.** The full-length cDNA for human Hsp27 was sub cloned into the lentiviral vector pHR'-CMV-EGFP at the *BamH*I and *Xho*I sites. Two vectors were created for this study: pHR-CMV-Hsp27 (Hsp27) and pHR-CMV (Mock) as previously described.8

**Chemotherapeutic agent.** Gemcitabine (Gemzar, Lilly Pharmaceutical Company, Suresnes, France) was kindly provided by Dr. Muracciole X (Timone Hospital, Marseilles, France).

---

**Figure 6** Total Hsp27, phospho-Hsp27 and elf4E levels in PC tumors. Immunohistochemistry analysis for Hsp27, P-Hsp27 and elf4E in human pancreas cancer tumors. Specimens from well-differentiated, moderately-differentiated, undifferentiated ADK and metastasis (liver, intraperitoneal) were stained with phospho-serine-15 (P-Ser 15), -78 (P-Ser 78) and -82 (P-Ser 82) Hsp27, total Hsp27 or elf4E in back to back sections.
ASO and siRNA sequences and treatment. Hsp27 ASO sequences were manufactured by ISIS Pharmaceuticals (Carlsbad, CA, USA) and supplied by OncoGenex Technologies (Vancouver, British Columbia, Canada) as previously described.17 The eIF4E siRNA was the Hs_eIF4E_1_HP validated siRNA from Qiagen (Courtaboeuf, France). The control siRNA was from the same source. Plated cells were treated with indicated siRNA or ASO concentrations according to the protocol previously described.22

Hsp27 deletion and phosphorylation mutant’s transfection. Histidine-tagged (His-tag) Hsp27 WT and three deletion mutants (N1, N2 and C1) in pcDNA4 containing His-tag epitope at N-terminal of the inserted fragment24 were kindly provided by Pr O’Brien (Ottawa University, Ontario, Canada). The phosphorylation mutants (3D and 3A) in pDEST26 (Invitrogen, Cergy Pontoise, France) containing His-tag at N-terminal of the inserted fragment were obtained after a gateway recombination with the phosphorylation mutants in pENTR kindly provided by Dr. William Gerthoffer (University of South Alabama, USA). MiaPaCa-2 cells were transfected with 10 μg WT, deletion or phosphorylation mutants using Fugene reagent (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. Cleared lysates were obtained 48 h post transfection according to our previous experiments.9

In vitro mitogenic assay. The in vitro growth effects were assessed in 12-well microtiter plates using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as previously described.9 MiaPaCa-2-Mock and -Hsp27 cells were treated with 150 mM gemcitabine, and MTT assays were performed 24 h. Wild-type MiaPaCa-2 cells were treated once daily with 70 nM OGX-427 for 2 days and MTT assays were performed 72 h after OGX-427 treatment. MiaPaCa-2 cells, transiently transfected or not with Hsp27 deletion mutants, were treated with gemcitabine during 48 h after transfection and cell viability was assayed 72 h later.

Flow cytometry analysis. Flow cytometry of propidium iodide-stained nuclei was performed as described previously.9 Briefly, MiaPaCa-2-Mock and -Hsp27 cells were treated with 150 mM gemcitabine. After 24 h, cells were analyzed for relative DNA content on a dual laser flow cytometer (Beckman Coulter Epics Elite, Beckman Inc., Miami, FL, USA). MiaPaCa-2 cells were treated once daily with OGX-427 for 2 days, and flow cytometry assays were performed 24 h after OGX-427 treatment.

Western blot analysis. Western blot analysis was performed as described previously9 using 1:5000 rabbit anti-Hsp27 polyclonal antibody (Assay designs, MI, USA), 1:1000 mouse anti-Hsp27 monoclonal antibody (Assay designs), 1:1000 rabbit anti-eIF4E polyclonal antibody (Cell Signaling technology, Inc.), 1:500 mouse anti-ubiquitin monoclonal antibody (Santa Cruz Biotechnology, Inc., Delaware, CA, USA) and 1:3000 mouse monoclonal histidine antibody (Sigma, St. Louis, MO, USA). Loading levels were normalized using 1:5000 rabbit anti-GAPDH polyclonal antibody or 1:2500 mouse anti-vinculin monoclonal antibody (Sigma).

Immunoprecipitation. Cleared lysates with adjusted protein concentration (Protein assay, BioRad, Marnes-la-Coquette, France) were used for immunoprecipitation with rabbit anti-Hsp27 antibody (Assay designs), rabbit anti-eIF4E antibody (Cell Signaling technology, Inc.), rabbit IgG (rgG; Millipore, Billerica, MA, USA) at 4 °C. Immune complexes were precipitated following 1-h incubation with 30 μl true blot rabbit beads (eBioscience SAS, Paris, France) at 4 °C. Complexes were suspended in protein sample buffer (BioRad) and boiled for 5 min.
Western Blot analysis was performed as previously described with secondary anti-mouse and anti-rabbit true blot HRP-conjugated antibodies (eBoSciences).

Assessment of in vivo tumor growth. For in vivo study, 1×10⁵ MiaPaCa-2 cells were inoculated s.c. with 0.1 ml of Matrigel (Becton Dickinson Labware, Franklin Lakes, NJ, USA) in the flank region of 4–5 week-old male athymic nude mice (Harlan Sprague Dawley, Indianapolis, IN) via 27-gauge needle. Tumors were measured weekly and their volumes were calculated by the formula: length × width × depth × 0.5236. When MiaPaCa-2 tumors reached 300–500 mm³, mice were randomly selected for treatment with OGX-427 alone, ASO control alone, OGX-427 and ASO control plus gemcitabine. Each experimental group consisted of 10 mice. After randomization, 10 mg/kg OGX-427 or ASO control was injected i.p. three times a week for 5 weeks. A total of 150 mg/kg gemcitabine was administered i.v. every 3 days from day 7 to 14 and from day 21 to 28. Data points were expressed as average tumor volume levels ± S.E.

Immunohistochemical determination of K67 and caspase-3 for proliferation index and in situ apoptosis. The expression of K67 and caspase-3 was detected in histological sections of tumor xenografts. Sections were cut from formalin-fixed and paraffin-embedded tissue blocks. The primary rabbit monoclonal anti-K67 (1:200) and caspase-3 (1:50) antibodies from Epitomic, Inc. (Burlingame, CA, USA) were added. The sections were incubated with diaminobenzidine substrate as chromogen.

Statistical analysis. All the results were expressed as mean ± S.E. Statistical analysis was performed by one-way ANOVA followed by Fisher’s protected least significant difference test (Statview 512, Brain Power Inc., Calabases, CA, USA). 

Conflict of Interest The University of British Columbia has submitted patent applications, listing Dr. Gleave and Dr. Rocchi as inventors, on the antisense sequence described in this paper. The University has submitted patent applications listing Dr. Gleave and Dr. Rocchi as inventors, on the antisense sequence described in this paper.

Acknowledgements We thank Pr. Edward O’Brien (Ottawa University, Canada) for providing the Hsp27 coding DNA/HIS deletion mutant vectors. We thank Dr. William Gershoffer (South Alabama University, USA) for providing the Hsp27 PENTR phosphorylation mutant vectors. We also thank Virginia Yago (Prostate Centre, Canada) for her excellent technical assistance in animal and laboratory experimentation. We thank Marie-Noëlle Lavaut for her excellent technical help for the immunohistochemistry. This work was supported by grants from the Institut National de la Santé et de la Recherche Médicale (INSERM), the Association pour la Recherche sur le Cancer (ARC), the Association pour la Recherche sur les Tumeurs de la Prostate (ARTP), the Institut national du cancer (InCa), the ligue contre le cancer, the agence nationale de la recherche (ANR) and the ministère de la recherche et de l’enseignement supérieur.

1. Van Laethem JL, Verslype C, Iovanna JL, Michi P, Conroy T, Louvet C et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2011; e-pub ahead of print 1 August 2011.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
3. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
4. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
5. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
6. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
7. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
8. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
9. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
10. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
11. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
35. Rosenwald IB, Rhoads DB, Callanan LD, Isselbacher KJ, Schmidt EV. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. *Proc Natl Acad Sci USA* 1993; 90: 6175–6178.

36. Othumpangat S, Kashon M, Joseph P. Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride. *J Biol Chem* 2005; 280: 25162–25169.

37. Pickart CM. Ubiquitin enters the new millennium. *Mol Cell* 2001; 8: 499–504.

38. Mitchell BS. The proteasome—an emerging therapeutic target in cancer. *N Engl J Med* 2003; 348: 2597–2598.

39. Kloppel G. Staging of pancreatic carcinoma. *Int J Pancreatol* 1991; 8: 203–204.

40. Garcia S, Dales JP, Jacquemier J, Charafe-Jauffret E, Birnbaum D, Andrac-Meyer L et al. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. *Br J Cancer* 2007; 96: 329–335.